NCT04688632 - Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 18, 2021

Primary Completion Date

March 13, 2021

Study Completion Date

March 26, 2021

Conditions

Symptomatic Neurogenic Orthostatic HypertensionnOH

Interventions

DRUG

Ampreloxetine <Dose A>

Ampreloxetine \<Dose A\> will be administered as 1 tablet of \<Dose A\> and 3 tablets of Ampreloxetine Placebo.

DRUG

Ampreloxetine <Dose B>

Ampreloxetine \<Dose B\> will be administered as 4 tablets of \<Dose A\>

DRUG

Ampreloxetine Placebo

Ampreloxetine Placebo will be administered as 4 tablets of placebo. The placebo tablet will match (in appearance) the ampreloxetine \<Dose A\> tablet.

DRUG

Moxifloxacin

Moxifloxacin will be administered orally as a single tablet.

DRUG

Moxifloxacin Placebo

Moxifloxacin placebo will be administered orally as a single tablet. The placebo tablet will match (in appearance) the moxifloxacin tablet.

Trial Locations (1)

85283

Theravance Biopharma Investigational Site, Tempe